BioWorld

Jan. 31, 2002

Amylin Seeks $92M Publicly To Fund AC2993 Phase IIIs

Amylin Pharmaceuticals Inc. started the second of three Phase III trials on AC2993, a compound designed to treat people with Type II diabetes by improving glucose control. (BioWorld Today) Read More

Signature Continues Acquisitions, Buys PDL’s Small-Molecule Unit

Signature BioScience Inc. is moving toward drug discovery and fueling the trek with acquisitions. (BioWorld Today) Read More

Scar Tissue In Injured Spinal Cord Acts As Barrier Preventing Normal Regeneration, Functional Recovery

IntraBiotics Netting $13.9M From Private Deal For Iseganan Studies

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for Dec. 11, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 11, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

US lawmakers demand that Kennedy be held accountable

BioWorld

As the systematic dismantling of the U.S. vaccine schedule escalates, the demands to hold Health and Human Services Secretary Robert Kennedy accountable are...

Medline plans record-setting $5.37B IPO

BioWorld MedTech

Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...